Health Costs

The MIDTERMS

Democrats Hold a Nearly 2-to-1 Advantage Over Republicans on Handling the Cost of Health Care

Poll: Cost of Health Care and Gas Top Voters’ Midterm Concerns; Democrats Hold Significant Advantage on Health Care Costs and Cost of Living 

With the 2026 midterms about a month away, health care costs remain tied with gas as voters’ top midterm concerns and the Democrats hold a clear edge over the Republicans Party on who voters trust to handle many top electoral issues, including the cost of health care and the cost of living. Two-thirds of U.S. adults now favor Medicare-for-all, a new high in KFF Polling, but support shifts when competing claims from critics and proponents are heard.

New and noteworthy

Health System Tracker

Is This A Healthcare Economy?

Health care employment has grown faster than other sectors of the economy, with jobs in physician offices, hospitals, outpatient care centers, home health, and other settings increasing over the past year even as the rest of the job market plateaued. 

U.S. Health Spending Is Expected to Reach $9 Trillion by 2034

How Much is Health Spending Expected to Grow?

This chart collection explores how much health spending is expected to grow in the coming years, with a look at growth in prescription drug spending, out-of-pocket spending, and related trends.

How TrumpRx Brand-Name Drug Prices Compare

TrumpRx prices for brand-name drugs are about as likely to be higher as lower compared to average prices in other wealthy countries, according to an analysis that compares 32 brand-name drugs.

Stay informed.

Stay informed.

Filter

311-320 of 1,627 results

  • 2023 Employer Health Benefits Chart Pack

    Feature

    This slideshow captures key data from the 2023 KFF Employer Health Benefits Survey survey, providing a detailed look at trends in employer-sponsored health coverage, including premiums, employee contributions, cost-sharing, abortion coverage, offer rates, wellness programs, and other employer practices.

  • 2023 Employer Health Benefits Survey

    Report

    This annual survey of employers provides a detailed look at trends in employer-sponsored health coverage, including premiums, worker contributions, cost-sharing provisions, offer rates, and more. This year’s report also looks at how employers are addressing a growing need for mental health services.

  • Benchmark Survey: Annual Family Premiums for Employer Coverage Rise 7% to Nearly $24,000 in 2023; Workers Contribute $6,575 on Average Now, But Potentially More Soon

    News Release

    Amid rising inflation, annual family premiums for employer-sponsored health insurance climbed 7% on average this year to reach $23,968, a sharp departure from virtually no growth in premiums last year, the 2023 benchmark KFF Employer Health Benefits Survey finds. On average, workers this year contribute $6,575 annually toward the cost of family premium, up nearly $500 from 2022, with employers paying the rest. Future increases may be on the horizon, as nearly a quarter (23%)…

  • KFF Health News, NPR, and CBS News Win Loeb Award for Series on Medical Debt in America

    News Release

    KFF Health News won the 2023 Loeb Award in the personal finance and consumer reporting category for its in-depth coverage of consumer medical debt in its “Diagnosis: Debt” series. In partnership with NPR and CBS News, KFF Health News examined the stories behind the more than 100 million people in America who have been pushed into debt by the nation’s health care system, revealing the epidemic of medical debt that has become a defining feature…

  • Consumer Survey Highlights Problems with Denied Health Insurance Claims

    Issue Brief

    This Data Note includes major findings from the KFF Consumer Survey on consumer experiences with claim denials. Among those who used the most health care over the past year, 27% experienced a denied claim. More consumers with private insurance experienced denied claims compared to Medicaid or Medicare.

  • The 4 Arguments You Will Hear Against Drug Price Negotiation

    Perspective

    As the Biden administration begins the process of negotiation drug prices for Medicare as authorized in the Inflation Reduction Act, KFF's Larry Levitt probes some of the arguments against it and the policy and political implications of the debate in this New York Times op-ed column.